Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03337035 · ClinicalTrials.gov registry record · Phase 1
Probiotics and Oxytocin Nasal Spray on Social Behaviors of Autism Spectrum Disorder (ASD) Children
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT03337035: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT03337035 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03337035, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
Because oral probiotics reported to potentially induce endogenous Oxytocin, and Oxytocin has been reported to improve social behaviors, the investigators will conduct a pilot trial to compare the effects of probiotics and Oxytocin on social behavioral changes in ASD children. Additionally, the investigators will check oxytocin levels, and perform brain fMRI in some subjects, in order to determine which treatment is more efficient, sustainable, and practical, and whether both treatments in combination are better than either treatment alone. If the trial is conclusive, the investigators will conduct a trial in large scale to understand more the mechanism of ASD behaviors and corresponding effective interventions.
Interventions
- DRUG intranasal oxytocin
- DIETARY_SUPPLEMENT oral probiotics
- DIETARY_SUPPLEMENT oral placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2019-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03337035
The ClinicalTrials.gov registry entry for NCT03337035 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which intranasal oxytocin is the first listed.
NCT03337035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03337035 about?
NCT03337035 is a clinical study titled "Probiotics and Oxytocin Nasal Spray on Social Behaviors of Autism Spectrum Disorder (ASD) Children". Because oral probiotics reported to potentially induce endogenous Oxytocin, and Oxytocin has been reported to improve social behaviors, the investigators will conduct a pilot trial to compare the effects of probiotics and Oxytocin on social behavioral changes in ASD children. Additionally, the inves...
What is the current status of trial NCT03337035?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2018-12-01. Estimated completion is 2019-10-02.
What interventions are being tested in trial NCT03337035?
The interventions under investigation include: intranasal oxytocin (DRUG), oral probiotics (DIETARY_SUPPLEMENT), oral placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03337035?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.